Stay updated on Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page
- Check6 days agoChange DetectedAccess to the NCT03290079 study record is now blocked by a 403 Forbidden page, replacing the previous study content and navigation. The change means users cannot view the trial details on ClinicalTrials.gov until access is restored.SummaryDifference18%

- Check14 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange Detected- The page now shows Revision: v3.6.6, replacing the previous v3.6.5, indicating a newer version of the study documentation.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page revision metadata has been updated to v3.6.5, signaling a minor version update to the study record documentation.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page now displays Revision: v3.6.4, replacing the previous v3.6.3. This reflects a newer page version without changing the study details or navigation.SummaryDifference0.1%

- Check85 days agoChange DetectedFooter credits now display the Moffitt Cancer Center branding and the full institution name, along with a new 'Helpful Links Provided by' label, and the site revision tag was updated from v3.6.2 to v3.6.3.SummaryDifference0.2%

- Check92 days agoChange DetectedThe page now displays a revision tag of v3.6.2, replacing the previous v3.6.0, indicating a recent site update to the page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.